Form 4: MapLight Therapeutics Grants Executive Equity Awards

MapLight Therapeutics' CAAO and PAO, Jonathan Gillis, received significant restricted stock units and stock options.

Summary

• Jonathan Gillis, Chief Accounting and Administrative Officer (CAAO) and Principal Accounting Officer (PAO) of MapLight Therapeutics, Inc. (MPLT), was granted equity awards.
• The awards include 6,020 Restricted Stock Units (RSUs) on February 5, 2026, with a price of $0 per unit.
• These RSUs represent a contingent right to receive one share of voting common stock each.
• The RSU vesting schedule is 1/4th on January 1, 2027, followed by 1/16th on each subsequent April 1, July 1, October 1, and January 1, contingent on continued service.
• Gillis also received 24,455 employee stock options on February 5, 2026, with an exercise price of $15.70 per share.
• The stock options have an expiration date of February 4, 2036.
• The option vesting schedule is 1/4th of the total shares on February 5, 2027, and 1/48th of the total shares each month thereafter, subject to continued service.
• Following these transactions, Gillis beneficially owns 254,523 shares of voting common stock directly and 24,455 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine executive compensation that aligns management incentives with long-term company performance and retention.

Positives

• The grant of 6,020 Restricted Stock Units (RSUs) and 24,455 employee stock options aligns the executive's interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options promote executive retention by requiring continued service over several years.

Future Outlook

The equity awards, with their multi-year vesting schedules, indicate an expectation of continued service from Jonathan Gillis and a long-term commitment to the company's performance.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to incentivize performance and ensure executive retention. These types of awards are common for officers in companies like MapLight Therapeutics, which are often in growth phases.

Stakeholder Impact

• Shareholders: The awards represent potential future dilution as RSUs convert to shares and options are exercised, but also align executive interests with shareholder value creation.
• Employees: Standard executive compensation practices can set a precedent for broader employee incentive programs.

Next Steps

• Continued service of Jonathan Gillis to meet vesting conditions for RSUs and stock options.
• Future vesting of 1/4th of RSUs on January 1, 2027, and subsequent 1/16th portions quarterly thereafter.
• Future vesting of 1/4th of stock options on February 5, 2027, and subsequent 1/48th portions monthly thereafter.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Equity Awards, Jonathan Gillis